Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

European Specialty Pharma In Transition: Is A U.S. Presence Necessary?

Executive Summary

European-based specialty pharma is at a crossroads. For several of the current generation of Shire PLC hopefuls – companies whose strategy, broadly defined, is focused on late-stage in-licensing and commercialization – 2011 could prove a transformational and, for some, a make-or-break year.
Advertisement

Related Content

Eyeing Solo U.S. Debut, EU Biotech ThromboGenics Preps Ocriplasmin For Launch
With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
European Spec Pharma Testing New Niches: Emerging Markets, Novel Products
Abstral Approval May Fetch ProStrakan The Valuation It's After
FDA Standardizes REMS Documents For Certain Fentanyl Products
Archimedes Raises £65 million for Leap to U.S.

Topics

Advertisement
UsernamePublicRestriction

Register

PS053031

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel